2019
Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
Srivastava G, Fox CK, Kelly AS, Jastreboff AM, Browne AF, Browne NT, Pratt JSA, Bolling C, Michalsky MP, Cook S, Lenders CM, Apovian CM. Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity. Obesity 2019, 27: 190-204. PMID: 30677262, PMCID: PMC6449849, DOI: 10.1002/oby.22385.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIntensive lifestyle interventionObesity pharmacotherapyLifestyle interventionSevere obesityPrediabetes/type 2 diabetesObesity-related comorbid diseasesNonalcoholic fatty liver diseasePediatric primary care providersIntensive lifestyle modificationFatty liver diseaseMore effective treatment strategiesObstructive sleep apneaEffective treatment optionPrimary care providersType 2 diabetesEffective treatment strategiesLifestyle modificationPharmacotherapy optionsBariatric surgeryComorbid diseasesLiver diseaseSleep apneaTreatment algorithmExcess adiposityInformed consent regulations
2018
The rs7903146 Variant in the TCF7L2 Gene Increases the Risk of Prediabetes/Type 2 Diabetes in Obese Adolescents by Impairing beta-Cell Function and Hepatic Insulin Sensitivity
C C, N S, L G, C D, C C, A G, R K, B P, M G, S C. The rs7903146 Variant in the TCF7L2 Gene Increases the Risk of Prediabetes/Type 2 Diabetes in Obese Adolescents by Impairing beta-Cell Function and Hepatic Insulin Sensitivity. 2018 DOI: 10.1530/ey.15.12.3.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply